Sector
PharmaceuticalsOpen
₹35.8Prev. Close
₹37.68Turnover(Lac.)
₹0.03Day's High
₹35.8Day's Low
₹35.852 Week's High
₹62.5652 Week's Low
₹14.85Book Value
₹29.45Face Value
₹10Mkt Cap (₹ Cr.)
21.09P/E
51.88EPS
0.69Divi. Yield
09 Sep 2024
12:00 AM
AGM
Announcement Date: 09 Sep, 2024
22 Oct 2024
12:00 AM
EGM
17 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.31 | -5.43 | -5.3 | -5.14 |
Net Worth | 1.22 | 1.1 | 1.23 | 1.39 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -0.05 | -0.09 | -0.07 | -0.03 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | -0.23 | -0.31 | 0 | -0.06 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.09 | -2.52 | -0.16 | 0.01 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | -31.43 | 166.89 | 31.01 | 18.5 |
EBIT growth | -24.06 | 15,191.52 | -96.91 | 110.74 |
Net profit growth | -24.1 | 15,171.95 | -96.92 | 110.79 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,663.15 | 93.33 | 3,99,045.4 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,841.15 | 82.22 | 1,81,611.04 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,477.3 | 24.79 | 1,19,322.68 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.05 | 59.72 | 1,13,003.55 | 474 | 0.18 | 2,385 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,259.2 | 19.53 | 1,05,090.54 | 1,200.7 | 0.63 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Prakash Shah
Company Sec. & Compli. Officer
Bhavana Tak
Independent Director
Avani Savjibhai Godhaniya
Independent Director
Dinesh Chander Notiyal
Executive Director
Mehul Hasmukhbhai Shah
G2 & G3 Samarpan Complex,
chakala Andheri East,
Maharashtra - 400099
Tel: -
Website: http://www.bacilpharma.com
Email: bacilpha@yahoo.com
E-2/3 Ansa Indl Est,
Saki Vihar Road, Sakinaka Andheri(E),
Mumbai - 400072
Tel: 91-22-40430200/28470
Website: www.bigshareonline.com
Email: investor@bigshareonline.com
Summary
Incorporated as a private limited company in Maharashtra in May 87, Bacil Pharma (BPL) was converted into a public limited company in Oct.90. The main business activity of the Company is Pharmaceutica...
Read More
Reports by Bacil Pharma Ltd
What is the Bacil Pharma Ltd share price today?
What is the Market Cap of Bacil Pharma Ltd?
What is the PE and PB ratio of Bacil Pharma Ltd?
What is the 52 Week High and Low of Bacil Pharma Ltd?
What is the CAGR of Bacil Pharma Ltd?
What is the shareholding pattern of Bacil Pharma Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.